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Abstract
Background: The herpes zoster burden of disease in Sweden is not well investigated. There is no Swedish
immunization program to prevent varicella zoster virus infections. A vaccine against herpes zoster and its
complications is now available. The aim of this study was to estimate the herpes zoster burden of disease and to
establish a pre-vaccination baseline of the minimum incidence of herpes zoster.
Methods: Data were collected from the Swedish National Health Data Registers including the Patient Register, the
Pharmacy Register, and the Cause of Death Register. The herpes zoster burden of disease in Sweden was estimated
by analyzing the overall, and age and gender differences in the antiviral prescriptions, hospitalizations and
complications during 2006-2010 and mortality during 2006-2009.
Results: Annually, 270 per 100,000 persons received antiviral treatment for herpes zoster, and the prescription rate
increased with age. It was approximately 50% higher in females than in males in the age 50+ population (rate ratio
1.39; 95% CI, 1.22 to 1.58). The overall hospitalization rate for herpes zoster was 6.9/100,000 with an approximately
three-fold increase for patients over 80 years of age compared to the age 70-79 group. A gender difference in
hospitalization rates was observed: 8.1/100,000 in females and 5.6/100,000 in males. Herpes zoster, with a registered
complication, was found in about one third of the hospitalized patients and the most common complications
involved the peripheral and central nervous systems. Death due to herpes zoster was a rare event.
Conclusions: The results of this study demonstrate the significant burden of herpes zoster disease in the pre-zoster
vaccination era. A strong correlation with age in the herpes zoster- related incidence, hospitalization, complications,
and mortality rates was found. In addition, the study provides further evidence of the female predominance in
herpes zoster disease.
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Background
Herpes zoster is a disease caused by reactivation of vari-
cella zoster virus (VZV), which occurs mainly in the eld-
erly population. Studies from Canada and the United
Kingdom have demonstrated an incidence rate of herpes
zoster over a lifetime of 28- 30% [1]. Complications such
as zoster ophtalmicus, bacterial superinfections, and
neurological manifestations i.e. meningitis, encephalitis,
and particularly post-herpetic neuralgia (PHN) are com-
mon [2]. With increasing age, the risk and severity of
complications is enhanced, and accompanied by a sub-
stantially higher hospitalization rate [3,4]. Several studies
have demonstrated a predominance of females contract-
ing herpes zoster [5].
Antiviral therapy has been used for decades to treat
herpes zoster. However, although it is effective in de-
creasing symptoms, studies on such therapy influencing
the incidence of the major complication postherpetic
neuralgia (PHN), are lacking [6,7]. In 2006, a live attenu-
ated herpes zoster vaccine received marketing authoriza-
tion in the US and EU after being shown to bring about
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a reduction in the incidence of herpes zoster and PHN
in individuals over 60 years of age in the Shingles Pre-
vention Study (SPS). It was demonstrated that the her-
pes zoster vaccine reduced the incidence of herpes
zoster by 51.3% and of PHN by 66.5% [8]. Recently, a
nearly 70% reduction of herpes zoster was found in per-
sons aged 50–59 after immunization with herpes zoster
vaccine [9].
The considerable morbidity related to VZV has prompted
some countries to implement prophylactic varicella vac-
cination [10,11]. In Sweden, there is no national pedi-
atric immunization programme against VZV and 98%
of Swedish 12-year olds showed serologic evidence of
prior VZV exposure according to a study conducted
in 1997 [12]. Hence, most adults in Sweden are at
potential risk of developing herpes zoster disease, es-
pecially late in life as immunosenescence progresses
[13] or during immunosuppression.
The herpes zoster burden of disease in Sweden has
not been well examined. In order to evaluate the need
for a herpes zoster vaccine and to establish a prevaccina-
tion baseline of herpes zoster burden in Sweden we con-
ducted a register-based study. The Swedish National
Patient Register and the Swedish National Pharmacy
Register contain respectively, data on all hospitalizations
and all drug prescriptions in Sweden respectively and
the Cause of Death Register contains mortality data re-
lated to cause.
The present study extracted gender-specific retrospect-
ive data from 2006–2010 concerning herpes zoster hospi-
talizations and drug prescriptions for antiviral medication
as well as zoster-related mortality during 2006–2009.
Methods
The Swedish National pharmacy register
The Swedish National Pharmacy Register contains infor-
mation on drugs distributed from all Swedish Pharma-
cies, the identity of the drug, doses and prices as well as
the patient’s gender, age, and place of residence. All pre-
scriptions are linked to the unique Swedish personal
identity number. This information makes it possible to
calculate both the number of prescriptions and the num-
ber of individual patients receiving medication. In
addition, the register includes information on the pre-
scribing doctor’s affiliation [14].
Data extraction from the Swedish National pharmacy
register
The following data were collected from the Swedish
National Pharmacy Register between January 1, 2006,
and December 31, 2010: gender, age, prescriptions of
acyclovir 800 mg × 5 or famciclovir 500 mg × 3 or vala-
cyclovir 1 g × 3 in packages for standard herpes zoster
treatment during 7 days. These treatment options are in
line with national and international recommendations
[15,16]. In addition, patient prescription information text
was collected whenever available. Since the antiviral
drugs mentioned above may be used in the treatment of
other diseases than herpes zoster. e.g. primary infections
of varicella zoster virus, and in some cases also in herpes
simplex infections, prescriptions containing one or more
of the following corresponding words in the patient in-
formation text were omitted: simplex, genital, mouth, la-
bial, varicella, prophylaxis, and chickenpox. For each
specific calender year within the study period, prescrip-
tions were linked to patients and counted only once, al-
though several prescriptions may have been assigned to
the same patient.
The Swedish National patient register
The Swedish National Patient Register covers 99.7% of all
public and private inpatient care units dating from 1987.
The patient register contains information on gender, age,
discharge diagnoses ICD-10 (on the two- and three digit
levels), as well as the duration of hospitalization [17]. In
Sweden, every citizen has a unique personal identity num-
ber [18] and this number is linked to each hospital stay.
In the registers, the number of dropouts and the num-
ber of stays with a missing personal identity number are
estimated to be less than 1%. The principal diagnosis is
missing in 1% of the hospitalizations [19].
Data extraction from the Swedish National patient register
Hospitalization rates (patients/100,000) and the number
of patients hospitalized were collected from the Swedish
National Patient Register between January 1, 2006, and
December 31, 2010. The ICD-10 codes investigated were:
B02.0 herpes zoster with encephalitis, B02.1 herpes zoster
meningitis, B02.2 herpes zoster with other complications
from the nervous system (ganglionitis, postherpetic poly-
neuropathy, postherpetic myelitis, trigeminal neuralgia,
other postherpetic nervous system involvement), B02.3
herpes zoster ocular disease, B02.7 disseminated herpes
zoster, B02.8 herpes zoster with other complications in-
cluding bacterial superinfection and B02.9 herpes zoster
without complication.
In the Swedish National Patient Register, both primary
and non-primary causes of all hospitalizations are re-
corded. In this study, data on herpes zoster as the pri-
mary and non-primary cause in hospitalization were
collected. However, for herpes zoster with complications
and age-stratified hospitalizations, only primary diagno-
sis cases are presented.
The Swedish National cause of death register and data
extraction
The Cause of Death Register covers approximately 98%
of Swedish deaths. The predecessor to the Register was
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started as early as 1749 and since 1951, it follows the
international standard. Since 1997, ICD-10 codes have
been utilized for input data. Death cause data related to
herpes zoster (ICD-10; B 02) and gender and age of dis-
eased persons have been collected [20] from January 1,
2006, to December 31, 2009.
Statistics
Descriptive statistics such as annual numbers and rates
per 100,000 population are presented. Trends in annual
numbers are assessed using linear regression, and rate
ratios are estimated and tested for differences between
men and women in different age groups. For each spe-
cific calender year within the study periods, prescrip-
tions and hospitalizations were linked to patients and
counted only once, although several events may have
been assigned to the same patient.
Ethical approval
The study was approved by the Regional Ethical Review
Board in Gothenburg (number 206–10).
Results
Prescriptions for antiviral medication related to herpes
zoster
Annually, approximately 25,500 patients received pre-
scriptions for antiviral medication in packages for stand-
ard herpes zoster treatment during 7 days (Table 1).
During the study period there was a trend towards an
increasing number of annual prescriptions. On average,
there was an annual increase of 655 prescriptions for
female patients (p = 0.035) and 403 for male patients
(p = 0.031) during the study period. Although a number
of prescriptions were given to patients between 30 and
49 years of age, there was a progressive increase in pre-
scriptions for patients over 50 years of age (Figure 1).
About half of the patients were prescribed acyclovir, while
the other half received valacyclovir (data not shown), and
a smaller number were prescribed famciclovir.
For prescription rates, a gender associated pattern with
a difference between males and females was discerned in
all age groups. The rate was approximately 50% higher
for females than in males in the age 50+ population (rate
ratio, 1.39; 95% CI, 1.22 to 1.58). The difference was
most pronounced in the 50–59 age group, where the
prescriptions rates were almost two-fold higher (rate ra-
tio, 1.81: 95% CI, 1.67 to 1.93) for females than for males
(Figure 1).
Hospitalizations related to herpes zoster
The average annual number of hospitalized patients di-
agnosed with herpes zoster as the primary cause was
636 over the study period. On including patients hospi-
talized with herpes zoster as both the primary or non-
primary cause, the average annual number of patients
was 1179 during the same period. The number of pa-
tients, the hospitalizations, and the average time of
hospitalization showed little or very low variability from
year to year during the study period. The average period
of hospitalization was approximately 7.5 days for cases
with a primary diagnosis and 10 days for cases with a
non-primary diagnosis (data not shown).
In the total population, the hospitalization rate for her-
pes zoster (primary cause) was 6.9/100,000. The corre-
sponding data (primary cause) were 8.1/100,000 and 5.6/
100,000 in females and males, respectively. For cases with
herpes zoster disease as the primary or non-primary diag-
nosis, the rate was 13.2/100,000 in the total population.
Hospitalizations for herpes zoster disease were rare in
individuals under 50 years of age. In the 50-year-old,
and older population, the mean annual hospitalization
rate (primary cause) for cases with herpes zoster disease
was significantly higher for females with 18.8 hospitaliza-
tions/100,000 compared to 13.7 hospitalizations/100,000
for males (Figure 2). In persons over 70 years of age the
hospitalizations rates were seen to accelerate with a sub-
sequent rapid increase for older age groups. The differ-
ence in hospitalization rates between males and females
was most pronounced in persons aged 80 years and
older (Figure 2).
Complications of herpes zoster
Herpes zoster with a registered complication was found in
33% of hospitalized females and 24% of hospitalized
males, (p < 0.001). For hospitalizations, herpes zoster with-
out complications (B02.9) was the most common diagno-
sis recorded. The most common complications were from
the peripheral and central nervous systems (B02.0, B02.1,
and B02.2). Other common complications were herpes
zoster opthalmicus (B02.3) and miscellanous complica-
tions, including bacterial superinfection (B02.8). Dissemi-
nated herpes zoster (B02.7) was rarely recorded (Table 2).
Herpes zoster mortality
The average annual mortality with herpes zoster as the
primary cause during the study period was low and the
Table 1 Annual number of female and male patients in
Sweden receiving antiviral prescriptions in the dosage
used in herpes zoster treatment during 2006-2010
Year Total Females Males
2006 24 405 15 107 9 298
2007 23 503 14 504 8 999
2008 25 291 15 668 9 623
2009 26 364 16 313 10 051
2010 28269 17480 10789
Reg coeff (p-value) 1058.9 (0.033) 655.5 (0.035) 403.4 (0.031)
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first cases of death occurred in the age groups 65 years
and older. In general, the mortality rates were higher in
women than in men. Mortality rates increased with age
and the oldest segment of the population had the high-
est mortality rate. The average annual mortality rate in
the age group 85 or older was five-fold higher compared
to that in the 80–84 age group (Figure 3). The average
annual mortality rate in the age group 50 and older age
group was 0.67/100,000 in females and 0.26/100,000 in
males. It should be noted that the cause of death is dir-
ectly related to the herpes zoster disease in the judgment
of the treating doctor.
Discussion
In this study we have estimated the burden of acute her-
pes zoster by utilizing National Swedish Health Care
Registers. The disease burden has been studied using three
separate approaches: analyzing antiviral medication pre-
scription data, demonstrating zoster-related hospitaliza-
tions, including complications, and herpes zoster-related
mortality. However, the study lacks an estimation of the
total burden of disease related to VZV reactivation since
analyses of prescriptions, hospitalizations, and mortality
related to PHN are not included in the analysis. A
strength of this study is the solid national data from the
Swedish National Patient Register with a very low number
of dropouts or lack of principal diagnoses, which are esti-
mated to occur in only one percent of cases, respectively
[19]. Primary care visits are not analyzed in this study be-
cause no national health care register has been established
for such visits in Sweden.
The Swedish National Pharmacy Register provides an
exclusive opportunity to analyze prescription patterns
since each prescription is linked to the unique personal
identity number of the patient. The prescription data
may be regarded as an indirect measurement of the her-
pes zoster incidence and primary care visits in Sweden.
This assumption is plausible since, in this study, most
antiviral medication prescriptions for herpes zoster were
found to be written by doctors in primary care (data not
Figure 1 Age-stratified number of male and female patients in Sweden receiving antiviral prescriptions in the dosage used in herpes
zoster treatment during 2006-2010.
Figure 2 Age-stratified annual hospitalization rates for herpes zoster disease as the primary diagnosis in males and females in Sweden
during 2006–2010.
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shown). Similar findings were reported in an Australian
study [21]. In Sweden, patients under 50 years of age are
not recommended antiviral treatment [15] and it was
found that approximately 70% of the prescriptions were
distributed to patients over 50 years of age. Thus, a the-
oretical association of the antiviral prescription data with
the incidence of herpes zoster is only feasible for the
population over 50-year-old population, and older. This
results in a national minimum incidence of herpes zoster
in Sweden of 621/100,000 for females and 404/100,000
for males in the population age 50 and older, based on
antiviral prescriptions. Recently, a review of European
studies, focusing on total population incidence of herpes
zoster, stated that in the 21 included studies the inci-
dence in all ages was 2–4.6/1000 inhabitants/year which
is in line with our results [22]. In the review by Thomas
et al., where studies from both Europe and USA were in-
cluded, the incidence in all ages varied from 3.6 to 14.2/
1000 inhabitants/year [5]. However, methodological dif-
ferences are frequent and direct comparisons of studies
must address this circumstance.
The analysis of the prescription data has some inher-
ent uncertainties. Even if precautions have been taken to
exclude prescriptions not related to herpes zoster, the
data may contain prescriptions for patients who received
antiviral treatment in the dosage for herpes zoster for
other indications than herpes zoster. However, the Swedish
Medical Product Agency does not recommend treatment
with dosages compatible with that used in herpes zoster
disease except for herpes simplex meningitis [16], a rela-
tively rare disease compared to herpes zoster disease. The
possible inclusion of non-herpes-zoster-related patients is
a limitation of the study and may result in an overesti-
mation of the prescription rates. On the other hand, the
number of patients with herpes zoster most likely exceeds
the number of prescriptions, since immunocompetent pa-
tients under 50 years of age with uncomplicated herpes
zoster are not recommended antiviral treatment in
Sweden [15]. In the review by Pinchinat et al. [22], pre-
scription studies were not considered as reliable as pro-
spective studies in health care facilities or retrospective
studies of herpes zoster cases identified through the re-
view of medical files when calculation the incidence of
herpes zoster. However, an overestimation of cases in our
study is less likely since only approximately 72% of the pa-
tients diagnosed (ICD −10) with herpes zoster in primary
care receive a prescription of antivirals (Dr. Lars Rombo,
personal communication).
In the present study, hospital cases with non-primary
and primary diagnoses of herpes zoster disease were ana-
lyzed. Herpes zoster occurs more often in elderly people,
but it is not unusual that hospitalization is the result of
other diseases. Thus, herpes zoster may be recorded as a
non-primary cause in these cases. At the same time, it
cannot be ruled out that patients with PHN might be mis-
diagnosed as a herpes zoster case in the group of non-
primary causes. On adding herpes zoster as a non-primary
diagnosis to the analysis, it was estimated that the annual
average number of hospitalized patients was 1,179, while
the annual average number of patients with a primary
diagnosis was 636. However, for the herpes zoster compli-
cations and age-stratified hospitalizations, only primary
Table 2 Average annual percentage and annual number
of patients hospitalized (primary diagnosis) in Sweden
for herpes zoster disease with or without complications
during the study period 2006 – 2010
Diagnosis Females % (n) Males % (n)
Zoster encephalitis (B02.0) 2.6 (10) 2.1 (5)
Zoster meningitis (B02.1) 1.8 (7) 2.1 (5)
Zoster with other nervous system
involvement (B02.2)
7.8 (29) 5.0 (13)
Zoster ocular disease (B02.3) 8.6 (33) 6.1 (16)
Disseminated zoster (B02.7) 2.4 (9) 2.9 (7)
Zoster with other complications (B02.8) 9.7 (37) 6.1 (16)
Zoster without complications (B02.9) 67.1 (254) 75.7 (195)
Figure 3 Annual age-specific mortality rate in patients with herpes zoster as the primary cause in Sweden during 2006–2009.
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diagnoses were examined to ensure a causal link to herpes
zoster.
The disease burden in hospitals is significant, expressed
in the rates of hospitalization, and is similar to that in a re-
cent report from France [4]. In the present study, the ma-
jority of the hospitalizations occurred in patients over
50 years of age. The increase in hospitalization rates
followed a particular pattern and there was a stepwise in-
crease between the age groups (Figure 2). In the group
80 years or older there was nearly a three-fold increase in
the hospitalization rates compared to the previous age-
group, reaching about 61/100,000 and 53/100,000 in fe-
males and males, respectively.
In a recent study from South Korea, it was demon-
strated that the hospitalization rates were increasing
from 2003 to 2007 [23]. It was speculated that this find-
ing was related to a relative increase in the size of the
elderly population along with an increasing number of
patients with immune deficiencies. We did not note
such an increase in hospitalization rates in our study.
However, the annual number of antiviral prescriptions for
herpes zoster increased by an average of 1,059 (p = 0.033)
during the study period. It is likely that cases of herpes
zoster will increase in the coming decades due to a grow-
ing elderly population. According to the National Popula-
tion Statistics in Sweden, the life expectancy in this
population is projected to increase from approximately
83.1 to 86.3 years in females and from 79.1 to 83.6 years
in males between the years 2009 and 2050.
Herpes zoster complications were recorded in approxi-
mately a third of hospitalized female cases while about a
fourth of male cases developed complications. Complica-
tions stemming from the peripheral and central nervous
systems dominated, quite similar to the findings in the
recent study in France [4]. There are reports of in-
creased numbers of cases detected after the introduction
of VZV quantitative PCR on cerebrospinal fluid samples
[24] and this method was implemented during the study
period in Sweden. Thus, nervous system involvement
may have been underestimated or underdiagnosed in the
study. Zoster with other complications, disseminated
herpes zoster, and zoster opthalmicus were also quite
common, demonstrating the broad spectrum of compli-
cations during herpes zoster disease. Bacterial super-
infections (which are included in zoster with other
complications) with septicemia and phlegmone are ser-
ious complications, nearly as common as the nervous
system complications.
The predominance of females was one of the major
findings in this study and was demonstrated in all the
analyses, i.e. the antiviral prescription, hospitalization
and mortality rates. The pattern of female predominance
was most pronounced for prescription rates where fe-
male patients had generally higher rates of prescription
of antivirals than males (rate ratio 1.61; 95% CI, 1.57 to
1.65). The female predominance was particularly evident
in the 50–59 age group where female patients had gen-
erally higher rates of prescription of antivirals compared
to males (rate ratio 1.83, 95% CI, 1.68 to 1.99). The pat-
tern of female predominance was also seen for hos-
pitalization rates, where females in all age-groups were
significantly more often hospitalized compared to males
(rate ratio 1.40; 95% CI, 1.20 to 1.64). In the European
review by Pinchinat et al., the incidence rates were sys-
tematically higher in females than in men in the in-
cluded studies confirming the results of this study
[22,25-28]. Even though a predominance in females of
antiviral prescriptions was demonstrated in several age
groups in the present study, it cannot be excluded that
this finding is related to a different health care seeking
pattern for herpes zoster between the sexes in Sweden
[29]. In addition, gender difference in the incidence of
herpes zoster might be due to immunological or hormo-
nal differences between men and women. However, this
issue is out of the scope of the present study and should
be further explored.
Conclusions
The results of the present analysis demonstrate the
strong correlation with age in the herpes zoster- related
incidence, hospitalization, complications, and mortality
rates in Sweden. In addition, the study provides further
evidence of the female predominance in herpes zoster
disease. The results of this study also provide a prevacci-
nation baseline for the herpes zoster burden in Sweden.
Many countries project a growing elderly population
and an increasing number of patients with treatments
suppressing the immune system. Hence, adequate strat-
egies need to be established to reduce the burden of her-
pes zoster today and in the future.
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